153 related articles for article (PubMed ID: 34009369)
1. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract][Full Text] [Related]
2. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of cancer and the benign call rate of afirma gene classifier in
Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
[TBL] [Abstract][Full Text] [Related]
5. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract][Full Text] [Related]
6. Performance of Afirma genomic sequencing classifier and histopathological outcome in Bethesda category III thyroid nodules: Initial versus repeat fine-needle aspiration.
Jin X; Lew M; Pantanowitz L; Iyengar JJ; Haymart MR; Papaleontiou M; Broome D; Sandouk Z; Raja SS; Hughes DT; Smola B; Jing X
Diagn Cytopathol; 2023 Nov; 51(11):698-704. PubMed ID: 37519144
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
Ahmadi S; Kotwal A; Bikas A; Xiang P; Goldner W; Patel A; Hughes EG; Longstaff X; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38415829
[TBL] [Abstract][Full Text] [Related]
8. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.
Morand GB; Tessler I; Noik M; Krasner J; Yamin T; Pusztaszeri MP; Avior G; Payne RJ
Endocr Pract; 2024 Apr; 30(4):319-326. PubMed ID: 38184241
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
Raghunathan R; Longstaff XR; Hughes EG; Li SJ; Sant VR; Tseng CH; Rao J; Wu JX; Yeh MW; Livhits MJ
Surgery; 2024 Jan; 175(1):221-227. PubMed ID: 37926582
[TBL] [Abstract][Full Text] [Related]
10. Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules.
Ladenson PW; Klopper JP; Hao Y; Kaushik P; Walsh PS; Huang J; Kloos RT; Ali SZ
Cancer Cytopathol; 2023 Oct; 131(10):609-613. PubMed ID: 37544986
[No Abstract] [Full Text] [Related]
11. Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing.
Mavromati M; Saiji E; Demarchi MS; Lenoir V; Seipel A; Kuczma P; Jornayvaz FR; Becker M; Fernandez E; De Vito C; Triponez F; Leboulleux S
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855426
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound Features and Performance of Afirma Gene Sequencing Classifier in Cytologically Indeterminate Thyroid Nodules.
Azaryan I; Endo M; Sipos JA; Ma J; Peng J; Nabhan F
J Endocr Soc; 2024 Jan; 8(3):bvae010. PubMed ID: 38348302
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of Molecular Data in Thyroid Nodules and Cancer.
Alzahrani AS
J Clin Endocrinol Metab; 2023 Oct; 108(11):2759-2771. PubMed ID: 37200449
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic interobserver agreement for thyroid fine-needle aspirates: Effects of reviewer experience and molecular diagnostics.
Gokozan HN; Mostyka M; Scognamiglio T; Solomon JP; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38656386
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases.
Shih KP; Lee YC; Tsai JJ; Lin SH; Liu CY; Li WS; Li CF; Hang JF
Endocr Pathol; 2024 Apr; ():. PubMed ID: 38642308
[TBL] [Abstract][Full Text] [Related]
16. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing.
Ye L; Zhou X; Huang F; Wang W; Qi Y; Xu H; Yang S; Shen L; Fei X; Xie J; Cao M; Zhou Y; Zhu W; Wang S; Ning G; Wang W
Nat Commun; 2017 Jun; 8():15533. PubMed ID: 28580939
[TBL] [Abstract][Full Text] [Related]
17. Testing of mutations on thyroid nodules with indeterminate cytology: A prospective study of 112 patients in Argentina.
Tolaba N; Spedaletti Y; Bazzoni P; Galindez M; Cerioni V; Santillan C; Richter G; Herrera C; Sanchez L; Van Cauwlaert L; Toscano MA; Nallar M; Monteros Alvi M; Moya CM
Endocrinol Diabetes Nutr (Engl Ed); 2021 Jun; ():. PubMed ID: 34172433
[TBL] [Abstract][Full Text] [Related]
18. Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
Iyer PC; Dadu R; Barque A; Zanelli C; Zheng X; Jiang H; Walsh PS; Hao Y; Huang J; Klopper J; Kloos RT; Cabanillas M
J Clin Endocrinol Metab; 2024 Mar; ():. PubMed ID: 38441247
[TBL] [Abstract][Full Text] [Related]
19. Associations between Bethesda categories and tumor characteristics of conventional papillary thyroid carcinoma.
Park VY; Kim EK; Kwak JY; Yoon JH; Moon HJ
Ultrasonography; 2018 Oct; 37(4):323-329. PubMed ID: 29361659
[TBL] [Abstract][Full Text] [Related]
20. Indolent behavior of malignant Bethesda III nodules compared to Bethesda V/VI nodules.
Endo M; Peng J; Nabhan FA; Brock P; Azaryan I; Long C; Ryan LE; Ringel MD; Sipos JA
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38415340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
